Tumor-associated antigens on circulating tumor cells

Tumor-associated antigens on circulating tumor cells refer to a heterogeneous group of cell-surface proteins or markers expressed by tumor cells that enter the bloodstream during the process of cancer metastasis. CTCs use a range of antigens for survival, immune evasion, intravasation, and extravasation as they travel from a primary tumor site to distant organs[1][3][4]. The best-known and clinically actionable antigens detectable on CTCs include EpCAM and cytokeratins, which are often used for diagnostic or prognostic biomarker purposes in liquid biopsy tests like CellSearch[2][4]. No single molecular entity called "tumor-associated antigen on CTCs" exists; rather, the surface antigen profile of CTCs varies by tumor type, EMT status, and individual patient, presenting major challenges for standardization in detection and targeting[1][3][5]. CTC antigens are mainly exploited for cancer diagnosis, prognosis, disease monitoring, and sometimes as exploratory therapeutic targets, yet they are not a single, canonical molecular target. This entry is conceptually "incorrect" as a discrete drug target: it refers to a class of antigens, not a single well-defined molecule. For downstream structuring or informatics, you should identify the specific antigen of interest (such as EpCAM, HER2, etc.) for precise information. The biological, diagnostic, and potential therapeutic significance of these CTC-associated antigens is high, but the diversity and heterogeneity of CTC marker expression remains a major limitation, both for research and clinical applications[1][3][4].

Other names

CTC surface antigensTumor cell surface markers on CTCsCTC-associated antigens